News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
295,445 Results
Type
Article (14352)
Company Profile (110)
Press Release (280983)
Section
Business (97310)
Career Advice (471)
Deals (17423)
Drug Delivery (64)
Drug Development (39864)
Employer Resources (49)
FDA (7045)
Job Trends (6548)
News (166033)
Policy (15457)
Tag
Academia (495)
Alliances (26557)
Alzheimer's disease (423)
Approvals (7054)
Artificial intelligence (69)
Bankruptcy (145)
Best Places to Work (4643)
Biotechnology (46)
Breast cancer (66)
Cancer (468)
Career advice (413)
Cell therapy (67)
Clinical research (33240)
Collaboration (212)
Compensation (80)
COVID-19 (850)
C-suite (60)
Data (486)
Diabetes (68)
Diagnostics (1705)
Drug discovery (45)
Drug pricing (59)
Earnings (35148)
Events (40762)
Executive appointments (225)
FDA (7314)
Funding (147)
Gene therapy (69)
GLP-1 (311)
Government (1395)
Healthcare (4148)
Infectious disease (872)
Inflammatory bowel disease (54)
Interviews (58)
IPO (6691)
Job creations (2129)
Job search strategy (379)
Layoffs (170)
Legal (3763)
Lung cancer (64)
Manufacturing (122)
Medical device (2224)
Medtech (2227)
Mergers & acquisitions (10820)
Metabolic disorders (203)
Neuroscience (544)
NextGen Class of 2024 (1691)
Non-profit (629)
Northern California (536)
Obesity (115)
Opinion (112)
Patents (65)
People (30426)
Pharmaceutical (67)
Phase I (8820)
Phase II (14161)
Phase III (12413)
Pipeline (220)
Policy (46)
Postmarket research (1446)
Preclinical (3531)
Radiopharmaceuticals (127)
Rare diseases (113)
Real estate (2898)
Regulatory (10912)
Research institute (600)
Resumes & cover letters (55)
Southern California (535)
Startups (1843)
United States (5273)
Vaccines (129)
Weight loss (82)
Date
Today (23)
Last 7 days (253)
Last 30 days (893)
Last 365 days (14051)
2024 (13983)
2023 (16100)
2022 (22800)
2021 (23374)
2020 (21937)
2019 (16684)
2018 (13051)
2017 (15468)
2016 (14650)
2015 (17260)
2014 (13928)
2013 (11943)
2012 (12848)
2011 (13344)
2010 (12125)
Location
Africa (337)
Arizona (44)
Asia (30572)
Australia (3954)
California (1258)
Canada (742)
China (184)
Colorado (47)
Connecticut (52)
Europe (45010)
Florida (186)
Illinois (141)
Indiana (96)
Japan (65)
Kansas (55)
Maryland (219)
Massachusetts (1069)
Minnesota (83)
New Jersey (542)
New York (374)
North Carolina (315)
Northern California (536)
Pennsylvania (331)
South America (550)
Southern California (535)
Texas (164)
Virginia (46)
Washington State (81)
295,445 Results for "faron pharmaceuticals ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024
Faron Pharmaceuticals Ltd. announces the nomination of its co-founders, Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, as finalists in the ‘SMEs’ category of the European Inventor Award 2024.
May 16, 2024
·
5 min read
Business
Faron Confirms Plans for the Coming Months Under New Leadership - April 16, 2024
Faron Pharmaceuticals Ltd. announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.
April 16, 2024
·
3 min read
Genetown
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting - September 22, 2023
Faron Pharmaceuticals Ltd. announces that the extraordinary general meeting of the Company took place , September 22, 2023 in Turku, Finland.
September 22, 2023
·
4 min read
Business
Faron’s Financial Statement Release January 1 to December 31, 2023
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, announced audited full-year financial results for January 1 to December 31, 2023 and provided an overview of recent corporate developments.
March 13, 2024
·
40 min read
Drug Development
Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
Faron Pharmaceuticals Ltd. announces it will host a virtual BEXMAB update event on Tuesday, March 19 at 11.00 EET/9am GMT, following the most recent data cut-off and scheduled analysis.
March 14, 2024
·
5 min read
Genetown
Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Faron Pharmaceuticals Ltd. announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023.
September 6, 2023
·
1 min read
Business
Faron Pharmaceuticals Notice of Half-Year Financial Results
Faron Pharmaceuticals Ltd will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.
August 4, 2023
·
5 min read
Business
Faron Pharmaceuticals Announces Board Changes - September 22, 2023
Faron Pharmaceuticals Ltd. is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjällskog as Non-Executive Directors of the Company with immediate effect following the passing of all resolutions put to shareholders of the Company at the Extraordinary General Meeting held earlier.
September 22, 2023
·
7 min read
Genetown
Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Faron Pharmaceuticals Oy announces that Dr. Markku Jalkanen, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday January 11, 2024, at 12pm PT, in San Francisco.
January 3, 2024
·
1 min read
Drug Development
Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
Faron Pharmaceuticals Ltd. announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care in patients with hypomethylating agents -refractory or relapsed myelodysplastic syndrome, an aggressive myeloid leukemia with very few treatment options.
January 9, 2024
·
6 min read
1 of 29,545
Next